Oventus Medical Limited announced that positive clinical data on Oventus' sleep treatment platform will be presented by Professor Danny Eckert and Benjamin Tong of Neuroscience Research Australia (NeuRA) at the European Respiratory Society (ERS) Congress in Paris, France between 15-19 September 2018. The presentations summarise data released by Oventus in May 2018 from two arms of the Company's ongoing "NeuRA study+". The ERS International Congress is the largest meeting of respiratory professionals in the world, with over 22,000 delegates in regular attendance. This year's meeting will specifically highlight the importance of environment in respiratory health and focus on the need to personalise respiratory medicine. Earlier this year the Company released data from the NeuRA study which showed that its range of products could treat 78% of patients without the need for CPAP and 100% of patients using the CPAP connect product which is in development. The two abstracts being presented at the congress further explore the personalised nature of Oventus' sleep medicine. The first abstract examines the effect of posture on nasal resistance, showing that nasal resistance increases not only when patients lay down on their back but also when they lay on their side. Oventus' ability to treat patients with increased nasal resistance may indicate the use of O2Vent oral appliance therapy in patients with posture dependent obstructive sleep apnoea, in effect extending the indications for the technology. The second dataset provides evidence that by combining the Oventus O2Vent oral appliance with a mask- free CPAP connection, severe obstructive sleep apnoea patients can be treated at lower pressures and without the need for a full face mask. About the NeuRA study and the $2.95m Australian Federal Government-funded CRC-P project: Targeted therapy for sleep apnoea: A novel personalised approach: The NeuRA study is being conducted as part of the $2.95 million Australian Federal Government-funded Cooperative Research Centres Programme (CRC-P) project, entitled, "Targeted therapy for sleep apnoea: A novel personalised approach". The project aims to improve the efficacy, compliance and monitoring of sleep apnoea therapy using a tailored suite of treatments to suit the needs of the individual patient. The range of therapies to be used, singularly or in combination, include oral appliances (with mandibular advancement and an airway) - with or without a positive airway pressure machine (with reduced pressure and air flow), supplemental oxygen delivery and/or a sleep consolidation aid. Oventus Medical is the lead participant together with Medical Monitoring Solutions Pty Ltd, Neuroscience Research Australia (NeuRA), Western Sydney University (WSU) and the CSIRO.